Innovation Pharmaceuticals Inc. (IPIX)
| Market Cap | 158.63K -90.0% |
| Revenue (ttm) | n/a |
| Net Income | -2.62M |
| EPS | -0.01 |
| Shares Out | 528.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,500 |
| Open | 0.0001 |
| Previous Close | 0.0003 |
| Day's Range | 0.0001 - 0.0003 |
| 52-Week Range | n/a |
| Beta | 148.25 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About IPIX
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellc... [Read more]
Financial Performance
Financial StatementsNews
Innovation Pharmaceuticals says BeaMed on track to file 510(k) submission
Innovation Pharmaceuticals provides shareholders with an update on recent progress in the development of BeaMed’s groundbreaking StingRay Laser System. BeaMed is a pioneering company dedicated to revo...
Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT ...
Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases
WAKEFIELD, MA, June 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced the United Stat...
Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing
WAKEFIELD, MA, June 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT B...
Innovation Pharmaceuticals Brilacidin antifungal research published
Innovation Pharmaceuticals announced publication of Brilacidin antifungal research in Nature Communications, a leading peer-reviewed scientific journal. To date, Brilacidin has demonstrated varying de...
Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications
WAKEFIELD, MA, April 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced publication o...
Innovation Pharmaceuticals announces new antifungal testing of Brilacidin
Innovation Pharmaceuticals announced that based on positive findings new testing of Brilacidin in additional in vitro and in vivo models against hard-to-treat fungal pathogens is planned by NIH/NIAID-...
Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers
WAKEFIELD, MA, March 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that based on ...
Innovation Pharmaceuticals enters research collaboration with USP
The Company and University of Sao Paulo, Brazil, have entered into a collaborative research agreement to investigate the broad-spectrum activity and treatment potential of Brilacidin in fungal disease...
Innovation Pharmaceuticals announces notice of allowance for U.S. patent
The Company wishes to inform shareholders that it was notified by the United States Patent and Trademark Office that US Patent Application 16/991812 – Host Defense Protein Mimetics for Prophylaxis…
Innovation Pharmaceuticals visits BeaMed about StingRay progress
Innovation Pharmaceuticals informs shareholders that development of the BeaMed StingRay Laser System is progressing smoothly and ahead of estimated schedule. The Company’s CEO and other financial stak...
Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission
WAKEFIELD, MA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT B...
Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement
Multiyear Development and Support Agreement Lays the Foundation for the Realization of an Advanced Software Suite to Enable Revolutionary Treatments of Epilepsy and Brain Tumors
Innovation Pharmaceuticals reports in vivo antifungal data on Brilacidin
Innovation Pharmaceuticals provided an update on ongoing research on the broad-spectrum antifungal activity of Brilacidin, the Company’s defensin mimetic drug candidate exhibiting antimicrobial and im...
Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin's Potential for Treating Fungal Keratitis
Additionally, Brilacidin to be Screened by NIH/NIAID to Further Characterize Its Broad-Spectrum Antifungal Activity
Innovation Pharmaceuticals says BeaMed receives FDA clearance for MANTA family
BT BeaMedical has notified Innovation Pharmaceuticals that it has received U.S. Food and Drug Administration clearance or its MANTA surgical laser family. The clearance is an important milestone for B...
Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family
Regulatory clearance lays key technological and regulatory foundation for BT BeaMedical's vision of revolutionizing treatment options in neurosurgery, oncology, and a wide spectrum of other clinical s...
NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy "Game-Changing Breakthrough"
Innovation Pharmaceuticals believes U.K. launch of MRgLITT for refractory focal epilepsy substantiates its investment in advanced laser technology of BT BeaMedical
Innovation Pharmaceuticals Announces Publication of Scientific Article on the Antifungal Activity of Brilacidin
WAKEFIELD, MA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced publication of ...
New In Vitro Data Supporting the Broad-Spectrum Antiviral Activity of Innovation Pharmaceuticals' Brilacidin Presented at 2022 Military Health System Research Symposium
Brilacidin shown to inhibit multiple alphaviruses, the bunyavirus Rift Valley Rift Fever, and Echovirus (a non-enveloped picornavirus) WAKEFIELD, MA / ACCESSWIRE / September 15, 2022 / Innovation Phar...
Innovation Pharmaceuticals' Investment in BT BeaMedical Helping Advance New Surgical Laser Platform
WAKEFIELD, MA / ACCESSWIRE / September 13, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today updated shareholders on recent progress by ...
Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated Researchers to Evaluate Brilacidin's Treatment Potential Against Monkeypox
WAKEFIELD, MA / ACCESSWIRE / August 5, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced that Brilacidin, the Company's defens...
Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical's Brilacidin as a Novel Oral Mucositis Drug Candidate
WAKEFIELD, MA / ACCESSWIRE / July 22, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provided an update on the Company's Brilacidin p...
Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium
Research was performed by scientists at George Mason University's Center for Infectious Disease Research (formerly NCBID) WAKEFIELD, MA / ACCESSWIRE / June 28, 2022 / Innovation Pharmaceuticals (OTCQB...
Innovation Pharmaceuticals Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing by NIH/NIAID-Sponsored and Rutgers University Researchers
WAKEFIELD, MA / ACCESSWIRE / June 23, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported that Brilacidin, the Company's defensin...